This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
VIA AILooking for an interpreter?
Remoto by ProZ.com connects you with an identity-verified interpreter by video or phone in about 60 seconds — 300+ languages, on demand or booked ahead.
Try Remoto »
Working languages:
English to Spanish
Client-vendor relationship recorded successfully!
Mariana Phillips has been added to your list of hired vendors.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Editing/proofreading
Expertise
Specializes in:
Medical: Health Care
Medical (general)
Medical: Pharmaceuticals
Nutrition
Also works in:
Chemistry; Chem Sci/Eng
Science (general)
More
Less
Rates
General rate: 0.1 USD per word
All accepted currencies
U. S. dollars (usd)
Portfolio
Sample translations submitted: 1
English to Spanish: Clinical Research Protocol General field: Medical Detailed field: Medical: Health Care
Source text - English Design: A 28-week, randomized, double-blind, placebo-controlled, observational study.
Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks.
Interventions: XXXX, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI.
Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for XXXX vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving XXXX vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving XXXX vs placebo.
Translation - Spanish Diseño: Estudio clínico observacional, aleatorizado, doble ciego, controlado con placebo, de 28 semanas de duración.
Lugar del estudio: Los pacientes asistieron al consultorio del médico sólo una vez para ser evaluados y recibir, de forma ciega, el medicamento para la duración total del estudio. Se programó un seguimiento telefónico cada cuatro semanas.
Intervención: XXXX, 42 µg administrados dos veces al día a través de un inhalador de dosis ajustada (MDI, por sus siglas en inglés), y placebo administrado dos veces al día a través de un MDI.
Mediciones y resultados: El estudio clínico se interrumpió después de hacer un análisis provisional de la información de 26,355 pacientes, debido a hallazgos en los pacientes afroamericanos y a dificultades en el reclutamiento. La frecuencia de la variable principal, mortalidad por causa respiratoria o eventos potencialmente mortales, fue baja y no se observó diferencia significativa entre el grupo tratado con XXXX o con placebo (50 vs. 36; riesgo relativo [RR] = 1,40; intervalo de confianza [IC] de 95 %; 0,91 a 2,14). Se observó un pequeño incremento significativo en la mortalidad por causa respiratoria (24 vs. 11; RR = 2,16; IC de 95 %; 1,06 a 4,41), en la mortalidad causada por asma (13 vs. 3; RR = 4,37; IC de 95 %; 1,25 a 15,34) y en la combinación de mortalidad causada por asma más eventos potencialmente mortales (37 vs. 22; RR = 1,71; IC de 95 %; 1,01 a 2,89), entre el grupo de pacientes que recibieron XXXX y los que recibieron placebo. El desequilibrio ocurrió principalmente en los pacientes afroamericanos; en la mortalidad por causa respiratoria o eventos potencialmente mortales (20 vs. 5; RR = 4,10; IC de 95 %; 1,54 a 10,90) y en la combinación de mortalidad causada por asma más eventos potencialmente mortales (19 vs. 4; RR = 4,92; IC de 95 %; 1,68 a 14,45) entre el grupo de pacientes que recibieron XXXX y los que recibieron placebo.
More
Less
Translation education
Other - New York University
Experience
Years of experience: 5. Registered at ProZ.com: Dec 2010.
Expertise 